Trulicity

Country: Evrópusambandið

Tungumál: enska

Heimild: EMA (European Medicines Agency)

Kauptu það núna

Vara einkenni Vara einkenni (SPC)
16-03-2023
Opinber matsskýrsla Opinber matsskýrsla (PAR)
16-03-2023

Virkt innihaldsefni:

dulaglutide

Fáanlegur frá:

Eli Lilly Nederland B.V.

ATC númer:

A10BJ05

INN (Alþjóðlegt nafn):

dulaglutide

Meðferðarhópur:

Drugs used in diabetes, Blood glucose lowering drugs, excl. insulins

Lækningarsvæði:

Diabetes Mellitus, Type 2

Ábendingar:

Trulicity is indicated for the treatment of patients 10 years and above with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance or contraindicationsin addition to other medicinal products for the treatment of diabetes.For study results with respect to combinations, effects on glycaemic control and cardiovascular events, and the populations studied, see sections 4.4, 4.5 and 5.1.

Vörulýsing:

Revision: 17

Leyfisstaða:

Authorised

Leyfisdagur:

2014-11-21

Upplýsingar fylgiseðill

                                72
B. PACKAGE LEAFLET
73
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
TRULICITY 0.75 MG SOLUTION FOR INJECTION IN PRE-FILLED PEN
TRULICITY 1.5 MG SOLUTION FOR INJECTION IN PRE-FILLED PEN
TRULICITY 3 MG SOLUTION FOR INJECTION IN PRE-FILLED PEN
TRULICITY 4.5 MG SOLUTION FOR INJECTION IN PRE-FILLED PEN
dulaglutide
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor, pharmacist or
nurse.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor, pharmacist or nurse.
This includes any possible
side effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Trulicity is and what it is used for
2.
What you need to know before you use Trulicity
3.
How to use Trulicity
4.
Possible side effects
5.
How to store Trulicity
6.
Contents of the pack and other information
1.
WHAT TRULICITY IS AND WHAT IT IS USED FOR
Trulicity contains an active substance called dulaglutide and is used
to lower blood sugar (glucose) in
adults and children aged 10 years and above, with type 2 diabetes
mellitus and can help prevent heart
disease.
Type 2 diabetes is a condition in which your body does not make enough
insulin, and the insulin that
your body produces does not work as well as it should.
When this happens, sugar (glucose) builds up in the blood.
Trulicity is used:
-
on its own if your blood sugar is not properly controlled by diet and
exercise alone, and you
can’t take metformin (another diabetes medicine).
-
or with other medicines for diabetes when they are not enough to
control your blood sugar
levels. These other medicines may be medicines taken by mouth and/or
insulin given by
injection.
It is important to continue to follow the advice on diet and exercise
given to you by your doctor,
pharmac
                                
                                Lestu allt skjalið
                                
                            

Vara einkenni

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Trulicity 0.75 mg solution for injection in pre-filled pen
Trulicity 1.5 mg solution for injection in pre-filled pen
Trulicity 3 mg solution for injection in pre-filled pen
Trulicity 4.5 mg solution for injection in pre-filled pen
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Trulicity 0.75 mg solution for injection in pre-filled pen
Each pre-filled pen contains 0.75 mg of dulaglutide* in 0.5 ml
solution.
Trulicity 1.5 mg solution for injection in pre-filled pen
Each pre-filled pen contains 1.5 mg of dulaglutide* in 0.5 ml
solution.
Trulicity 3 mg solution for injection in pre-filled pen
Each pre-filled pen contains 3 mg of dulaglutide* in 0.5 ml solution.
Trulicity 4.5 mg solution for injection in pre-filled pen
Each pre-filled pen contains 4.5 mg of dulaglutide* in 0.5 ml
solution.
*produced in CHO cells by recombinant DNA technology.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Solution for injection.
Clear, colourless solution.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Type 2 Diabetes Mellitus
Trulicity is indicated for the treatment of patients 10 years and
above with insufficiently controlled
type 2 diabetes mellitus as an adjunct to diet and exercise
•
as monotherapy when metformin is considered inappropriate due to
intolerance or
contraindications
•
in addition to other medicinal products for the treatment of diabetes.
For study results with respect to combinations, effects on glycaemic
control and cardiovascular events,
and the populations studied, see sections 4.4, 4.5 and 5.1.
3
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
_ _
Posology
_Adults _
_ _
_Monotherapy _
The recommended dose is 0.75 mg once weekly.
_Add-on therapy_
The recommended dose is 1.5 mg once weekly.
If needed,
•
the 1.5 mg dose can be increased after at least 4 weeks to 3 mg once
weekly.
•
the 3 mg dose can be increased after at least 4 weeks to 4.5 mg once
weekly.
The maximum dose is 4.5 mg once weekly.
_Paediatri
                                
                                Lestu allt skjalið
                                
                            

Skjöl á öðrum tungumálum

Upplýsingar fylgiseðill Upplýsingar fylgiseðill búlgarska 16-03-2023
Vara einkenni Vara einkenni búlgarska 16-03-2023
Opinber matsskýrsla Opinber matsskýrsla búlgarska 16-03-2023
Upplýsingar fylgiseðill Upplýsingar fylgiseðill spænska 16-03-2023
Vara einkenni Vara einkenni spænska 16-03-2023
Opinber matsskýrsla Opinber matsskýrsla spænska 16-03-2023
Upplýsingar fylgiseðill Upplýsingar fylgiseðill tékkneska 16-03-2023
Vara einkenni Vara einkenni tékkneska 16-03-2023
Opinber matsskýrsla Opinber matsskýrsla tékkneska 16-03-2023
Upplýsingar fylgiseðill Upplýsingar fylgiseðill danska 16-03-2023
Vara einkenni Vara einkenni danska 16-03-2023
Opinber matsskýrsla Opinber matsskýrsla danska 16-03-2023
Upplýsingar fylgiseðill Upplýsingar fylgiseðill þýska 16-03-2023
Vara einkenni Vara einkenni þýska 16-03-2023
Opinber matsskýrsla Opinber matsskýrsla þýska 16-03-2023
Upplýsingar fylgiseðill Upplýsingar fylgiseðill eistneska 16-03-2023
Vara einkenni Vara einkenni eistneska 16-03-2023
Opinber matsskýrsla Opinber matsskýrsla eistneska 16-03-2023
Upplýsingar fylgiseðill Upplýsingar fylgiseðill gríska 16-03-2023
Vara einkenni Vara einkenni gríska 16-03-2023
Opinber matsskýrsla Opinber matsskýrsla gríska 16-03-2023
Upplýsingar fylgiseðill Upplýsingar fylgiseðill franska 16-03-2023
Vara einkenni Vara einkenni franska 16-03-2023
Opinber matsskýrsla Opinber matsskýrsla franska 16-03-2023
Upplýsingar fylgiseðill Upplýsingar fylgiseðill ítalska 16-03-2023
Vara einkenni Vara einkenni ítalska 16-03-2023
Opinber matsskýrsla Opinber matsskýrsla ítalska 16-03-2023
Upplýsingar fylgiseðill Upplýsingar fylgiseðill lettneska 16-03-2023
Vara einkenni Vara einkenni lettneska 16-03-2023
Opinber matsskýrsla Opinber matsskýrsla lettneska 16-03-2023
Upplýsingar fylgiseðill Upplýsingar fylgiseðill litháíska 16-03-2023
Vara einkenni Vara einkenni litháíska 16-03-2023
Opinber matsskýrsla Opinber matsskýrsla litháíska 16-03-2023
Upplýsingar fylgiseðill Upplýsingar fylgiseðill ungverska 16-03-2023
Vara einkenni Vara einkenni ungverska 16-03-2023
Opinber matsskýrsla Opinber matsskýrsla ungverska 16-03-2023
Upplýsingar fylgiseðill Upplýsingar fylgiseðill maltneska 16-03-2023
Vara einkenni Vara einkenni maltneska 16-03-2023
Opinber matsskýrsla Opinber matsskýrsla maltneska 16-03-2023
Upplýsingar fylgiseðill Upplýsingar fylgiseðill hollenska 16-03-2023
Vara einkenni Vara einkenni hollenska 16-03-2023
Opinber matsskýrsla Opinber matsskýrsla hollenska 16-03-2023
Upplýsingar fylgiseðill Upplýsingar fylgiseðill pólska 16-03-2023
Vara einkenni Vara einkenni pólska 16-03-2023
Opinber matsskýrsla Opinber matsskýrsla pólska 16-03-2023
Upplýsingar fylgiseðill Upplýsingar fylgiseðill portúgalska 16-03-2023
Vara einkenni Vara einkenni portúgalska 16-03-2023
Opinber matsskýrsla Opinber matsskýrsla portúgalska 16-03-2023
Upplýsingar fylgiseðill Upplýsingar fylgiseðill rúmenska 16-03-2023
Vara einkenni Vara einkenni rúmenska 16-03-2023
Opinber matsskýrsla Opinber matsskýrsla rúmenska 16-03-2023
Upplýsingar fylgiseðill Upplýsingar fylgiseðill slóvakíska 16-03-2023
Vara einkenni Vara einkenni slóvakíska 16-03-2023
Opinber matsskýrsla Opinber matsskýrsla slóvakíska 16-03-2023
Upplýsingar fylgiseðill Upplýsingar fylgiseðill slóvenska 16-03-2023
Vara einkenni Vara einkenni slóvenska 16-03-2023
Opinber matsskýrsla Opinber matsskýrsla slóvenska 16-03-2023
Upplýsingar fylgiseðill Upplýsingar fylgiseðill finnska 16-03-2023
Vara einkenni Vara einkenni finnska 16-03-2023
Opinber matsskýrsla Opinber matsskýrsla finnska 16-03-2023
Upplýsingar fylgiseðill Upplýsingar fylgiseðill sænska 16-03-2023
Vara einkenni Vara einkenni sænska 16-03-2023
Opinber matsskýrsla Opinber matsskýrsla sænska 16-03-2023
Upplýsingar fylgiseðill Upplýsingar fylgiseðill norska 16-03-2023
Vara einkenni Vara einkenni norska 16-03-2023
Upplýsingar fylgiseðill Upplýsingar fylgiseðill íslenska 16-03-2023
Vara einkenni Vara einkenni íslenska 16-03-2023
Upplýsingar fylgiseðill Upplýsingar fylgiseðill króatíska 16-03-2023
Vara einkenni Vara einkenni króatíska 16-03-2023
Opinber matsskýrsla Opinber matsskýrsla króatíska 16-03-2023

Leitaðu viðvaranir sem tengjast þessari vöru

Skoða skjalasögu